Strategies to target long-lived plasma cells for treating hemophilia A inhibitors

Chao Lien Liu, Meghan J. Lyle, Simon C. Shin, Carol H. Miao

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Long-lived plasma cells (LLPCs) can persistently produce anti-factor VIII (FVIII) antibodies which disrupt therapeutic effect of FVIII in hemophilia A patients with inhibitors. The migration of plasma cells to BM where they become LLPCs is largely controlled by an interaction between the chemokine ligand CXCL12 and its receptor CXCR4. AMD3100 combined with G-CSF inhibit their interactions, thus facilitating the mobilization of CD34+ cells and blocking the homing of LLPCs. These reagents were combined with anti-CD20 to reduce B-cells and the specific IL-2/IL-2mAb (JES6-1) complexes to induce Treg expansion for targeting anti-FVIII immune responses. Groups of mice primed with FVIII plasmid and protein respectively were treated with the combined regimen for six weeks, and a significant reduction of anti-FVIII inhibitor titers was observed, associated with the dramatic decrease of circulating and bone marrow CXCR4+ plasma cells. The combination regimens are highly promising in modulating pre-existing anti-FVIII antibodies in FVIII primed subjects.

Original languageEnglish
Pages (from-to)65-73
Number of pages9
JournalCellular Immunology
Volume301
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Factor VIII
Hemophilia A
Plasma Cells
CXCR4 Receptors
Chemokine CXCL12
Antibodies
Therapeutic Uses
Granulocyte Colony-Stimulating Factor
Interleukin-2
Plasmids
B-Lymphocytes
Bone Marrow
Ligands
Proteins

Keywords

  • AMD3100
  • Factor VIII
  • G-CSF
  • Hemophilia A
  • Immune tolerance
  • Immunomodulation
  • Inhibitors
  • Plasma cells

ASJC Scopus subject areas

  • Immunology

Cite this

Strategies to target long-lived plasma cells for treating hemophilia A inhibitors. / Liu, Chao Lien; Lyle, Meghan J.; Shin, Simon C.; Miao, Carol H.

In: Cellular Immunology, Vol. 301, 01.03.2016, p. 65-73.

Research output: Contribution to journalArticle

Liu, Chao Lien ; Lyle, Meghan J. ; Shin, Simon C. ; Miao, Carol H. / Strategies to target long-lived plasma cells for treating hemophilia A inhibitors. In: Cellular Immunology. 2016 ; Vol. 301. pp. 65-73.
@article{17132c16aa514f369bb07d8e0f0245e0,
title = "Strategies to target long-lived plasma cells for treating hemophilia A inhibitors",
abstract = "Long-lived plasma cells (LLPCs) can persistently produce anti-factor VIII (FVIII) antibodies which disrupt therapeutic effect of FVIII in hemophilia A patients with inhibitors. The migration of plasma cells to BM where they become LLPCs is largely controlled by an interaction between the chemokine ligand CXCL12 and its receptor CXCR4. AMD3100 combined with G-CSF inhibit their interactions, thus facilitating the mobilization of CD34+ cells and blocking the homing of LLPCs. These reagents were combined with anti-CD20 to reduce B-cells and the specific IL-2/IL-2mAb (JES6-1) complexes to induce Treg expansion for targeting anti-FVIII immune responses. Groups of mice primed with FVIII plasmid and protein respectively were treated with the combined regimen for six weeks, and a significant reduction of anti-FVIII inhibitor titers was observed, associated with the dramatic decrease of circulating and bone marrow CXCR4+ plasma cells. The combination regimens are highly promising in modulating pre-existing anti-FVIII antibodies in FVIII primed subjects.",
keywords = "AMD3100, Factor VIII, G-CSF, Hemophilia A, Immune tolerance, Immunomodulation, Inhibitors, Plasma cells",
author = "Liu, {Chao Lien} and Lyle, {Meghan J.} and Shin, {Simon C.} and Miao, {Carol H.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.cellimm.2016.01.005",
language = "English",
volume = "301",
pages = "65--73",
journal = "Cellular Immunology",
issn = "0008-8749",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Strategies to target long-lived plasma cells for treating hemophilia A inhibitors

AU - Liu, Chao Lien

AU - Lyle, Meghan J.

AU - Shin, Simon C.

AU - Miao, Carol H.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Long-lived plasma cells (LLPCs) can persistently produce anti-factor VIII (FVIII) antibodies which disrupt therapeutic effect of FVIII in hemophilia A patients with inhibitors. The migration of plasma cells to BM where they become LLPCs is largely controlled by an interaction between the chemokine ligand CXCL12 and its receptor CXCR4. AMD3100 combined with G-CSF inhibit their interactions, thus facilitating the mobilization of CD34+ cells and blocking the homing of LLPCs. These reagents were combined with anti-CD20 to reduce B-cells and the specific IL-2/IL-2mAb (JES6-1) complexes to induce Treg expansion for targeting anti-FVIII immune responses. Groups of mice primed with FVIII plasmid and protein respectively were treated with the combined regimen for six weeks, and a significant reduction of anti-FVIII inhibitor titers was observed, associated with the dramatic decrease of circulating and bone marrow CXCR4+ plasma cells. The combination regimens are highly promising in modulating pre-existing anti-FVIII antibodies in FVIII primed subjects.

AB - Long-lived plasma cells (LLPCs) can persistently produce anti-factor VIII (FVIII) antibodies which disrupt therapeutic effect of FVIII in hemophilia A patients with inhibitors. The migration of plasma cells to BM where they become LLPCs is largely controlled by an interaction between the chemokine ligand CXCL12 and its receptor CXCR4. AMD3100 combined with G-CSF inhibit their interactions, thus facilitating the mobilization of CD34+ cells and blocking the homing of LLPCs. These reagents were combined with anti-CD20 to reduce B-cells and the specific IL-2/IL-2mAb (JES6-1) complexes to induce Treg expansion for targeting anti-FVIII immune responses. Groups of mice primed with FVIII plasmid and protein respectively were treated with the combined regimen for six weeks, and a significant reduction of anti-FVIII inhibitor titers was observed, associated with the dramatic decrease of circulating and bone marrow CXCR4+ plasma cells. The combination regimens are highly promising in modulating pre-existing anti-FVIII antibodies in FVIII primed subjects.

KW - AMD3100

KW - Factor VIII

KW - G-CSF

KW - Hemophilia A

KW - Immune tolerance

KW - Immunomodulation

KW - Inhibitors

KW - Plasma cells

UR - http://www.scopus.com/inward/record.url?scp=84959180691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959180691&partnerID=8YFLogxK

U2 - 10.1016/j.cellimm.2016.01.005

DO - 10.1016/j.cellimm.2016.01.005

M3 - Article

C2 - 26877251

AN - SCOPUS:84959180691

VL - 301

SP - 65

EP - 73

JO - Cellular Immunology

JF - Cellular Immunology

SN - 0008-8749

ER -